Live
FierceBiotechWhy Execution Excellence Now Defines Biopharma WinnersFierceBiotechHow integrated strategy is reshaping biopharma growthFierceBiotechBiotech value creation at an inflection pointFierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regressionPharmaVoice3 potential takeover targets in obesityFierceBiotechHow Unlearn is building a scientific intelligence layer for clinical developmentFierceBiotechHow AI is reshaping biopharma decision-makingFierceBiotechBiopharma IPOs: Timing, capital and staying flexibleRoche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical TechnologyEndpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealEndpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealEndpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3B
FierceBiotech 26. Nov. 2025

FDA delays decision on Ascendis' dwarfism prospect by 3 months

FDA delays decision on Ascendis' dwarfism prospect by 3 months

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.